A Real-World data of 100 Day outcomes of Multiple Myeloma patients undergoing Autologous Stem Cell Transplant using Non-Cryopreserved Stem Cells

Aims: To evaluate the day 100 outcomes of ASCT using non-cryopreserved stem cells in MM patients. Methods: The study included seventy patients who underwent ASCT with non-cryopreserved stem cells for MM between January 2009 and September 2023 at Armed Forces Bone Marrow Transplant Centre, Rawalpindi Pakistan.Patients were followed up to day +100 post-transplant in terms of their platelets and neutrophil engraftment, transplant related mortality, its associated complications and duration of hospitalisation. Results: The median age of the patients at the time of transplant was 49.97(+-9.79) years. Male to female ratio was 3:1. The most common presenting symptom was backache (70%) while anaemia was the usual initial laboratory findings (73%). The Mobilization strategy in the majority of patients (70%) was Chemotherapy granulocyte colony stimulating factor, and most of the patients (55%) were in complete remission (CR) at the time of ASCT. The conditioning regimen used commonly (85%) was Melphalan 200 mg/m2. The median days for engraftment of neutrophils and platelets were 11(IQR 10.75-12) days and 16 (IQR 15-18) days, respectively. The median duration of hospitalisation after transplant was14 days (IQR: 13 to 16). Febrile neutropenia was documented in 80.3% patients. Overall and disease-free survival was 100% at day 100. Conclusion: Non-cryopreserved stem cells offer a cheaper, convenient and effective alternative for the cryopreserved stem cells. Non-cryopreserved stem cells were associated with rapid neutrophil and platelet engraftment and should be preferred stem cell source in resource limited centres. Conflict of ineterest: The full manuscript including this abstract is already publised in "History of Medicine" journaland is submitted to this journal after invitation due to poster presentation at First international conference of Transplantation at Marriot Hotel Karachi.